deltatrials
Terminated EARLY_PHASE1 INTERVENTIONAL 1-arm NCT03208712

Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy

Pilot Trial of Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy

Sponsor: University of Michigan Rogel Cancer Center

Conditions Urothelial Carcinoma
Interventions Atezolizumab Radium-223
Updated 9 times since 2017 Last updated: Oct 22, 2018 Started: Nov 1, 2017 Primary completion: Aug 2, 2018 Completion: Aug 2, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low accrual

Other terminated trials from University of Michigan Rogel Cancer Center

See all terminations from University of Michigan Rogel Cancer Center

Other Urothelial Carcinoma trials with similar outcome

Browse all Urothelial Carcinoma trials

Listed as NCT03208712, this EARLY_PHASE1 trial focuses on Urothelial Carcinoma and remains terminated or withdrawn. Sponsored by University of Michigan Rogel Cancer Center, it has been updated 9 times since 2017, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Aug 2017 – ~Dec 2017 · 4 months · monthly snapshotNot Yet Recruiting~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshotRecruiting~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshotRecruiting~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshotActive Not Recruiting~Nov 2018 – ~Feb 2019 · 3 months · monthly snapshotTerminated~Feb 2019 – ~Jan 2021 · 23 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated EARLY_PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated EARLY_PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated EARLY_PHASE1

  4. Feb 2019 — Jan 2021 [monthly]

    Terminated EARLY_PHASE1

  5. Nov 2018 — Feb 2019 [monthly]

    Terminated EARLY_PHASE1

    Status: Active Not Recruiting → Terminated

▶ Show 4 earlier versions

  1. Sep 2018 — Nov 2018 [monthly]

    Active Not Recruiting EARLY_PHASE1

    Status: Recruiting → Active Not Recruiting

  2. Jun 2018 — Sep 2018 [monthly]

    Recruiting EARLY_PHASE1

  3. Dec 2017 — Jun 2018 [monthly]

    Recruiting EARLY_PHASE1

    Status: Not Yet Recruiting → Recruiting

  4. Aug 2017 — Dec 2017 [monthly]

    Not Yet Recruiting EARLY_PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of Michigan Rogel Cancer Center
Data source: University of Michigan Rogel Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations